Despite showing clinical benefit in treating a number of cancers, PDT clinical adoption has been encumbered by its complexity and lingering phototoxicity that challenges the management of patients and their quality of life. Our therapeutic solution overcomes these obstacles in offering simplified administration of PDT that combines an automated light delivery and real-time dosimetry system paired with a 2nd-generation photosensitizer with superior tumor targeting and negligible side effects.

Lumeda is developing a comprehensive therapy for treating lung cancer in which PDT selectively destroys tumor cells locally, while potentiating the immune system to work in combination with immune checkpoint blockade to recognize and attack residual and distant disease cells. While our focus is on bringing this therapy mainstream in the treatment of late-stage lung cancer, our DigiLum™ technology is a platform that can address unmet needs in other cancers.  Current targets fall under two distinct proprietary PDT light delivery methods that can be applied in standard of care surgical interventions.

  1. Surface Applicator PDT
    • VATS / Laparoscopic Intervention
    • Earlier Stage II/III NSCLC
    • Ovarian/Primary Peritoneal Cancer
    • Colorectal Cancer
  1. Minimally Invasive/Interstitial PDT
    • Endoscopic / Robotically-Assisted Intervention
    • Hepatobiliary Cancers
    • Pancreatic Cancer

Lumeda is conducting a thorough review process of the cancers listed to best identify where PDT could address standard of care treatment gaps, and scope the clinical development plan to bring a PDT solution forward.